Huntington National Bank reduced its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 1.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 135,500 shares of the healthcare conglomerate’s stock after selling 1,892 shares during the quarter. Huntington National Bank’s holdings in UnitedHealth Group were worth $26,538,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in UNH. Davis R M Inc. raised its position in UnitedHealth Group by 45.2% during the 3rd quarter. Davis R M Inc. now owns 3,587 shares of the healthcare conglomerate’s stock worth $703,000 after buying an additional 1,117 shares during the last quarter. Raymond James Trust N.A. increased its holdings in shares of UnitedHealth Group by 1.0% during the 3rd quarter. Raymond James Trust N.A. now owns 56,317 shares of the healthcare conglomerate’s stock valued at $11,030,000 after purchasing an additional 566 shares in the last quarter. Xact Kapitalforvaltning AB increased its holdings in shares of UnitedHealth Group by 1.7% during the 3rd quarter. Xact Kapitalforvaltning AB now owns 178,227 shares of the healthcare conglomerate’s stock valued at $34,906,000 after purchasing an additional 2,896 shares in the last quarter. Mizuho Securities USA LLC purchased a new position in shares of UnitedHealth Group during the 3rd quarter valued at approximately $2,998,000. Finally, Personal Capital Advisors Corp increased its holdings in shares of UnitedHealth Group by 6.6% during the 3rd quarter. Personal Capital Advisors Corp now owns 130,619 shares of the healthcare conglomerate’s stock valued at $25,582,000 after purchasing an additional 8,032 shares in the last quarter. 85.97% of the stock is owned by hedge funds and other institutional investors.
In other UnitedHealth Group news, CEO Larry C. Renfro sold 22,598 shares of UnitedHealth Group stock in a transaction on Friday, December 15th. The shares were sold at an average price of $221.75, for a total transaction of $5,011,106.50. Following the sale, the chief executive officer now owns 195,314 shares of the company’s stock, valued at approximately $43,310,879.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas E. Roos sold 975 shares of UnitedHealth Group stock in a transaction on Thursday, October 19th. The stock was sold at an average price of $205.47, for a total transaction of $200,333.25. Following the sale, the insider now directly owns 24,630 shares in the company, valued at approximately $5,060,726.10. The disclosure for this sale can be found here. Insiders sold a total of 34,630 shares of company stock worth $7,669,416 in the last three months. 0.89% of the stock is owned by corporate insiders.
UnitedHealth Group (NYSE:UNH) last released its quarterly earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.09. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The firm had revenue of $50.32 billion for the quarter, compared to analysts’ expectations of $50.38 billion. During the same quarter last year, the company earned $2.17 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. equities analysts expect that UnitedHealth Group Incorporated will post 9.99 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Friday, December 1st were paid a $0.75 dividend. The ex-dividend date was Thursday, November 30th. This represents a $3.00 dividend on an annualized basis and a yield of 1.36%. UnitedHealth Group’s dividend payout ratio is currently 33.26%.
Several research firms have recently weighed in on UNH. Zacks Investment Research lowered shares of UnitedHealth Group from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Oppenheimer lifted their target price on shares of UnitedHealth Group from $215.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Raymond James Financial reaffirmed a “buy” rating on shares of UnitedHealth Group in a report on Wednesday, December 6th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $208.00 target price on shares of UnitedHealth Group in a report on Tuesday, October 17th. Finally, Morgan Stanley lifted their target price on shares of UnitedHealth Group from $215.00 to $235.00 and gave the company an “overweight” rating in a report on Wednesday, October 18th. Three investment analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the stock. UnitedHealth Group currently has a consensus rating of “Buy” and a consensus price target of $224.56.
COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/23/unitedhealth-group-incorporated-unh-shares-sold-by-huntington-national-bank.html.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
What are top analysts saying about UnitedHealth Group? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for UnitedHealth Group and related companies.